Prophylaxis of the antiphospholipid syndrome:: a consensus report

被引:61
作者
Alarcón-Segovia, D
Boffa, MC
Branch, W
Cervera, R
Gharavi, A
Khamashta, M
Shoenfeld, Y
Wilson, W
Roubey, R
机构
[1] Inst Nacl Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Mexico City 14000, DF, Mexico
[2] Hosp Pitie Salpetriere, Dept Internal Med, Paris, France
[3] Univ Utah, Hlth Sci Ctr, Dept Obstet & Gynecol, Salt Lake City, UT USA
[4] Hosp Clin Barcelona, Dept Autoimmune Dis, Inst Clin Infecc & Immunol, Barcelona, Catalonia, Spain
[5] Morehouse Sch Med, Atlanta, GA 30310 USA
[6] St Thomas Hosp, Rayne Inst, Lupus Res Unit, London SE1 7EH, England
[7] Sheba Med Ctr, Res Ctr Autoimmune Dis, Tel Hashomer, Israel
[8] Louisiana State Univ, Hlth Sci Ctr, Dept Med, Rheumatol Sect, New Orleans, LA 70112 USA
[9] Univ N Carolina, Div Rheumatol & Immunol, Chapel Hill, NC USA
关键词
anti-beta-2-glycoprotein; anticoagulation; antiphospholipid antibodies; low-dose aspirin; pregnancy loss; systemic lupus erythematosus; thrombosis prevention;
D O I
10.1191/0961203303lu388oa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypothetical circumstances that may require prophylaxis for a potential antiphospholipid syndrome (primary prophylaxis), or in some instances when there already had been some manifestations of the syndrome (secondary prophylaxis), were presented to a panel of experts for their consideration on potential prophylactic intervention. These were subsequently presented to the participants in the First International Consensus on Treatment of the Antiphospholipid Syndrome. In most instances there was consensus in adding low dose aspirin, an exception being aspirin allergy when other antiaggregants could be used in nonpregnant subjects. General measures to prevent thrombosis and other vaso-protective actions should also be provided. Higher risk of fetal loss or thrombosis called for anticoagulation with coumadin in nonpregnant subjects or subcutaneous low molecular weight heparin in pregnant ones. When indicated, prophylaxis of the antiphospholipid syndrome should be provided in systemic lupus erythematosus patients who are being treated for their disease. In no instance should corticosteroids or immunosuppresants be given as prophylactic of an antiphospholipid syndrome.
引用
收藏
页码:499 / 503
页数:5
相关论文
共 10 条
  • [1] Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome
    Blank, M
    Krause, I
    Fridkin, M
    Keller, N
    Kopolovic, J
    Goldberg, I
    Tobar, A
    Shoenfeld, Y
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (06) : 797 - 804
  • [2] A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
    Erkan, D
    Yazici, Y
    Peterson, MG
    Sammaritano, L
    Lockshin, MD
    [J]. RHEUMATOLOGY, 2002, 41 (08) : 924 - 929
  • [3] Erkan D, 2001, ARTHRITIS RHEUM, V44, P1466, DOI 10.1002/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO
  • [4] 2-C
  • [5] GALLI M, IN PRESS BLOOD
  • [6] ANTICARDIOLIPIN ANTIBODIES AND THE RISK FOR ISCHEMIC STROKE AND VENOUS THROMBOSIS
    GINSBURG, KS
    LIANG, MH
    NEWCOMER, L
    GOLDHABER, SZ
    SCHUR, PH
    HENNEKENS, CH
    STAMPFER, MJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 117 (12) : 997 - 1002
  • [7] Serum anti-β2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients
    Gómez-Pacheco, L
    Villa, AR
    Drenkard, C
    Cabiedes, J
    Cabral, AR
    Alarcón-Segovia, D
    [J]. AMERICAN JOURNAL OF MEDICINE, 1999, 106 (04) : 417 - 423
  • [8] THE MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME
    KHAMASHTA, MA
    CUADRADO, MJ
    MUJIC, F
    TAUB, NA
    HUNT, BJ
    HUGHES, GRV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (15) : 993 - 997
  • [9] Petri M., 1994, Arthritis and Rheumatism, V37, pS297
  • [10] Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies -: Do the benefits outweigh the risks?: A decision analysis
    Wahl, DG
    Bounameaux, H
    de Moerloose, P
    Sarasin, FP
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (13) : 2042 - 2048